Literature DB >> 22855434

Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma.

Gilda Tonziello1, Marintonietta Pisaturo, Antonello Sica, Maria Giovanna Ferrara, Caterina Sagnelli, Giuseppe Pasquale, Evangelista Sagnelli, Salvatore Guastafierro, Nicola Coppola.   

Abstract

A female patient with non-Hodgkin lymphoma who tested positive for surface antigen of the hepatitis B virus and negative for hepatitis B core antibody experienced a reactivation of occult HBV infection 20 months after rituximab discontinuation despite lamivudine prophylaxis covering the 4 months of rituximab administration and the subsequent 12 months.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22855434     DOI： 10.1007/s15010-012-0305-y

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  27 in total

Review 1.  Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.

Authors:  Winnie Yeo; Philip J Johnson
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

2.  Chronic hepatitis B.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2007-02       Impact factor: 17.425

Review 3.  EASL Clinical Practice Guidelines: management of chronic hepatitis B.

Authors: 
Journal:  J Hepatol       Date:  2008-10-29       Impact factor: 25.083

4.  Surveillance and treatment protocols to detect and treat hepatitis B virus reactivation in hepatitis B surface antigen-negative/antibody to hepatitis B core antigen-positive patients receiving chemotherapy for onco-hematologic malignancies.

Authors:  Massimo Marignani; Alfredo Marzano
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

5.  Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.

Authors:  Nozomi Niitsu; Yuki Hagiwara; Ken Tanae; Mika Kohri; Naoki Takahashi
Journal:  J Clin Oncol       Date:  2010-09-13       Impact factor: 44.544

6.  Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.

Authors:  Dongmei Ji; Junning Cao; Xiaonan Hong; Junmin Li; Jianmin Wang; Fangyuan Chen; Chun Wang; Shanhua Zou
Journal:  Eur J Haematol       Date:  2010-05-20       Impact factor: 2.997

7.  Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy.

Authors:  D Francisci; F Falcinelli; E Schiaroli; M Capponi; B Belfiori; L Flenghi; F Baldelli
Journal:  Infection       Date:  2009-11-10       Impact factor: 3.553

8.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

9.  HBV superinfection in HCV chronic carriers: a disease that is frequently severe but associated with the eradication of HCV.

Authors:  Evangelista Sagnelli; Nicola Coppola; Mariantonietta Pisaturo; Addolorata Masiello; Gilda Tonziello; Caterina Sagnelli; Vincenzo Messina; Pietro Filippini
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

Review 10.  Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation.

Authors:  Shing-Yan Ma; George K K Lau; Vincent C C Cheng; Raymond Liang
Journal:  Leuk Lymphoma       Date:  2003-08
View more
  18 in total

Review 1.  Clinical impact of occult hepatitis B virus infection in immunosuppressed patients.

Authors:  Evangelista Sagnelli; Mariantonietta Pisaturo; Salvatore Martini; Pietro Filippini; Caterina Sagnelli; Nicola Coppola
Journal:  World J Hepatol       Date:  2014-06-27

Review 2.  Occult HBV infection in the oncohematological setting.

Authors:  C Sagnelli; M Macera; M Pisaturo; R Zampino; M Coppola; E Sagnelli
Journal:  Infection       Date:  2016-04-13       Impact factor: 3.553

Review 3.  Treatment of rheumatic diseases and hepatitis B virus coinfection.

Authors:  Anna Felis-Giemza; Marzena Olesińska; Katarzyna Świerkocka; Ewa Więsik-Szewczyk; Ewa Haładyj
Journal:  Rheumatol Int       Date:  2014-12-31       Impact factor: 2.631

Review 4.  Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention Strategies.

Authors:  Oluwatobi O Ozoya; Lubomir Sokol; Samir Dalia
Journal:  J Clin Transl Hepatol       Date:  2016-06-15

Review 5.  Primary Cutaneous B-Cell Lymphomas: An Update.

Authors:  Paola Vitiello; Antonello Sica; Andrea Ronchi; Stefano Caccavale; Renato Franco; Giuseppe Argenziano
Journal:  Front Oncol       Date:  2020-05-27       Impact factor: 6.244

6.  Cancer- and Non-cancer Related Chronic Pain: From the Physiopathological Basics to Management.

Authors:  Antonello Sica; Beniamino Casale; Maria Teresa Di Dato; Armando Calogero; Alessandro Spada; Caterina Sagnelli; Mario Santagata; Pietro Buonavolontà; Alfonso Fiorelli; Anna Salzano; Concetta Anna Dodaro; Erika Martinelli; Elisabetta Saracco; Teresa Troiani; Dario Tammaro; Fortunato Ciardiello; Alfonso Papa
Journal:  Open Med (Wars)       Date:  2019-10-17

7.  Chronic Chest Pain Control after Trans-Thoracic Biopsy in Mediastinal Lymphomas.

Authors:  Antonello Sica; Beniamino Casale; Caterina Sagnelli; Maria Teresa Di Dato; Marco Rispoli; Mario Santagata; Pietro Buonavolontà; Alfonso Fiorelli; Paola Vitiello; Stefano Caccavale; Massimiliano Creta; Anna Maria Salzano; Evangelista Sagnelli; Elisabetta Saracco; Giuseppe Gazzerro; Vincenzo Famiglietti; Dario Tammaro; Alfonso Papa
Journal:  Healthcare (Basel)       Date:  2021-05-18

8.  Concurrent infection of hepatitis B virus negatively affects the clinical outcome and prognosis of patients with non-Hodgkin's lymphoma after chemotherapy.

Authors:  Jie Chen; Jianmin Wang; Jianmin Yang; Weiping Zhang; Xianmin Song; Li Chen
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

9.  Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma.

Authors:  Junichi Muraishi; Michihiko Shibata; Yuichi Honma; Masaaki Hiura; Shintaro Abe; Masaru Harada
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

Review 10.  The impact of the SARS-CoV-2 infection, with special reference to the hematological setting.

Authors:  Antonello Sica; Danilo Casale; Giovanni Rossi; Beniamino Casale; Massimo Ciccozzi; Morena Fasano; Marco Ciotti; Evangelista Sagnelli; Alfonso Papa; Caterina Sagnelli
Journal:  J Med Virol       Date:  2020-07-11       Impact factor: 20.693
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.